New drug combo tested for Tough-to-Treat blood cancer
NCT ID NCT03118466
Summary
This study tested whether adding the drug lenalidomide to a standard three-drug chemotherapy regimen (MEC) could improve outcomes for adults with acute myeloid leukemia (AML) that has returned after treatment or didn't respond to initial therapy. The goal was to see if this combination could help more patients achieve remission and stay in remission longer. The trial enrolled 41 participants to evaluate the safety and effectiveness of this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02062, United States
-
Massachusetts general Hospital
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.